Anti-SMYD3 Monoclonal Antibody for WB, IF/ICC, ELISA - Q9H7B4

Core Product Specifications and Parameters

Biological Background: SMYD3 Function and Localization

• SMYD3 (SET and MYND domain-containing protein 3) is a histone-lysine N-methyltransferase that specifically methylates histone H3 at lysine 4 (H3K4me2/me3) and histone H4 at lysine 5 (H4K5me). Related references: PMID:15235609 PMID:22419068
• It functions as a transcriptional co-activator by binding DNA sequences 5'-CCCTCC-3' or 5'-GAGGGG-3' and associating with RNA polymerase II complexes. Related references: PMID:15235609
• The protein is also known as KMT3E, ZMYND1, and ZNFN3A1, and contains a SET domain for methyltransferase activity and a MYND-type zinc finger domain.
• SMYD3 is localized in both the cytoplasm and nucleus, and its expression is tissue-specific, with high levels in skeletal muscle and testis.
• It is overexpressed in a majority of colorectal and hepatocellular carcinomas, suggesting a role in tumorigenesis.
• Post-translational modifications include acetylation and phosphorylation; the protein is a zinc-binding chromatin regulator involved in epigenetic control.
• Alternative splicing produces multiple isoforms, and the full-length protein has a molecular weight of approximately 49 kDa.

Experimental Guidance and Technical Tips

• The immunogen is a synthetic peptide from amino acids 200-300 of human SMYD3, which corresponds to a region within the catalytic SET domain. This antibody may recognize both unmodified and modified forms; validation for specific PTM contexts is recommended.
• This antibody has been tested in Western blot (WB), immunofluorescence/immunocytochemistry (IF/ICC), and ELISA. For WB, a band at ~49 kDa is expected. Appropriate loading controls and blocking conditions should be optimized.
• Cross-reactivity with mouse and rat SMYD3 is reported; however, sequence alignment of the immunogen region should be confirmed in the relevant species to ensure specificity.
• Given the overexpression in certain cancers, this antibody may be useful in cancer tissue arrays or cell lines; however, validation in the specific experimental system is necessary.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. This SMYD3 monoclonal antibody, targeting a key epigenetic regulator, is part of our extensive portfolio supporting chromatin biology and oncology research. We offer validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and customized sourcing for rare target raw materials to streamline your diagnostic development.